In vitro study of the pulmonary translocation of nanoparticles - A preliminary study

被引:98
作者
Geys, J
Coenegrachts, L
Vercammen, J
Engelborghs, Y
Nemmar, A
Nemery, B
Hoet, PHM
机构
[1] Katholieke Univ Leuven, Lab Pneumol, Unit Lung Toxicol, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium
关键词
rat type II pneumocytes; calu-3 cell line; in vitro; TEER; nanoparticles;
D O I
10.1016/j.toxlet.2005.07.005
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 [卫生毒理学];
摘要
Recent studies indicate that inhaled ultrafine particles can pass into the circulation. To study this translocation in an in vitro model three types of pulmonary epithelial cells were examined. The integrity of the cell monolayer was verified by measuring the transepithelial electrical resistance (TEER) and passage of sodium fluorescein. TEER was too low in A549 cells. In these preliminary experiments, TEER values of 1007 +/- 300 and 348 +/- 62 Omega cm(2) were reached for the Calu-3 cell line, using permeable membranes of 0.4 and 3 mu m pore size, respectively. Growing primary rat type II pneumocytes on 0.4 mu m pores, a TEER value of 241 +/- 90 Omega cm(2) was reached on day 5; on 3 mu m pores, no acceptable high TEER value was obtained. Translocation studies were done using 46 nm fluorescent polystyrene particles. When incubating polystyrene particles on membranes without a cellular monolayer, significant translocation was only observed using 3 mu m pores: 67.5% and 52.7% for carboxyl- and amine-modified particles, respectively. Only the Calu-3 cell line was used in an initial experiment to investigate the translocation: on 0.4 mu m pores no translocation was observed, on 3 mu m pores similar to 6% translocation was observed both for carboxyl- and amine-modified particles. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:218 / 226
页数:9
相关论文
共 27 条
[1]
In-vitro nasal drug delivery studies: comparison of derivatised, fibrillar and polymerised collagen matrix-based human nasal primary culture systems for nasal drug delivery studies [J].
Agu, RU ;
Jorissen, M ;
Willems, T ;
Augustijns, P ;
Kinget, R ;
Verbeke, N .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (11) :1447-1456
[2]
[Anonymous], 2004, TECHNOLOGICAL ANAL I
[3]
TIGHT MONOLAYERS OF RAT ALVEOLAR EPITHELIAL-CELLS - BIOELECTRIC PROPERTIES AND ACTIVE SODIUM-TRANSPORT [J].
CHEEK, JM ;
KIM, KJ ;
CRANDALL, ED .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (03) :C688-C693
[4]
The potential environmental impact of engineered nanomaterials [J].
Colvin, VL .
NATURE BIOTECHNOLOGY, 2003, 21 (10) :1166-1170
[5]
STIMULATION OF NET ACTIVE ION-TRANSPORT ACROSS ALVEOLAR TYPE-II CELL MONOLAYERS [J].
COTT, GR ;
SUGAHARA, K ;
MASON, RJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 250 (02) :C222-C227
[6]
Putrescine uptake by alveolar epithelial cell monolayers exhibiting differing transepithelial electrical resistances [J].
Dickinson, PA ;
Evans, JP ;
Farr, SJ ;
Kellaway, IW ;
Appelqvist, TP ;
Hann, AC ;
Richards, RJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (10) :1112-1116
[7]
Nanotoxicology [J].
Donaldson, K ;
Stone, V ;
Tran, CL ;
Kreyling, W ;
Borm, PJA .
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2004, 61 (09) :727-728
[8]
Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3) [J].
Florea, BI ;
van der Sandt, ICJ ;
Schrier, SM ;
Kooiman, K ;
Deryckere, K ;
de Boer, AG ;
Junginger, HE ;
Borchard, G .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (07) :1555-1563
[9]
Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery [J].
Foster, KA ;
Avery, ML ;
Yazdanian, M ;
Audus, KL .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 208 (1-2) :1-11
[10]
Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism [J].
Foster, KA ;
Oster, CG ;
Mayer, MM ;
Avery, ML ;
Audus, KL .
EXPERIMENTAL CELL RESEARCH, 1998, 243 (02) :359-366